R. Allegro

发表

Cigarette Smoking and Drinking Water Source: Correlation with Clinical Features and Pathology of Superficial Bladder Carcinoma

G. Morgia, G. Carrieri, A. Di Lallo, 2009, Urologia Internationalis.

Is Free/Total PSA Predictive of Pathological Stage and Gleason Score in Patients with Prostate Cancer and Serum PSA ≤10 ng/ml?

F. Pietropaolo, F. Aragona, P. Pepe, 2006, Urologia Internationalis.

Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.

G. Morgia, G. Carrieri, A. Di Lallo, 2013, Urology.

Preliminary Report of a Multicentric Study on Environmental Risk Factors in Ta-T1 Transitional Cell Carcinoma of the Bladder

G. Morgia, M. Pavone-Macaluso, L. Cindolo, 2006, Urologia Internationalis.

Validation of a Commercial Loop-Mediated Isothermal Amplification (LAMP)-Based Kit for the Detection of Salmonella spp. According to ISO 16140:2016

F. Geraci, C. Di Bella, Antonella Costa, 2021, Applied Sciences.

Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment.

V. Serretta, F. Aragona, A. Ruggirello, 2008, The Journal of urology.

Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double‐blinded randomized study between single or combination therapy (PROCOMB trial)

M. Carini, A. Minervini, G. Morgia, 2014, The Prostate.

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma

R. Tomasino, V. Morello, V. Serretta, 2003, Journal of Cancer Research and Clinical Oncology.

Risk Assessment of Cadmium, Lead, and Mercury on Human Health in Relation to the Consumption of Farmed Sea Bass in Italy: A Meta-Analytical Approach

S. Sadok, C. Di Bella, P. Schembri, 2021, Frontiers in Marine Science.

TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.

V. Serretta, C. Pavone, R. Allegro, 2004, European urology.

Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study

V. Serretta, A. Ruggirello, D. Melloni, 2010 .

Prediction by quantitative histology of pathological stage in prostate cancer.

R Allegro, F Aragona, F. Fraggetta, 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study].

V. Serretta, A. Ruggirello, D. Melloni, 2010, Urologia.

A 1‐year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non‐muscle‐invasive bladder cancer

G. Morgia, M. Battaglia, A. Di Lallo, 2010, BJU international.

Results at 48 Months of a Randomized Trial on Maintenance after Early Adjuvant

G. Morgia, A. Siragusa, M. Falsaperla, 2009 .

[Results at 48 months of a randomized trial on maintenance after early adjuvant].

G. Morgia, M. Falsaperla, F. Nicolosi, 2009, Urologia.

A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

G. Morgia, V. Gebbia, F. Ferraù, 2012, Clinical genitourinary cancer.

Is PSA density still useful in diagnosing prostate cancer?

F. Fraggetta, F. Aragona, P. Pepe, 2009, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients

A. Martorana, V. Serretta, F. Aragona, 2008, Prostate Cancer and Prostatic Diseases.

Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.

M. Carini, A. Minervini, A. Russo, 2019, Clinical genitourinary cancer.

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

G. Cicero, V. Franco, V. Serretta, 2015, Urology annals.

Medial tunica degeneration of the ascending aortic wall is associated with specific microRNA changes in bicuspid aortic valve disease

A. Pitruzzella, G. Ruvolo, F. Cappello, 2021, Molecular medicine reports.

Long‐term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12‐year results of a phase II study

V. Serretta, C. Pavone, R. Allegro, 2003, BJU international.

Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.

V. Serretta, C. Pavone, R. Allegro, 2005, Urology.

1041 MONTHLY MAINTENANCE AFTER EARLY INTRAVESICAL CHEMOTHERAPY

G. Morgia, F. Selvaggi, G. Carrieri, 2010 .

Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital

G. Morgia, A. Siragusa, M. Falsaperla, 2009, Urologia internationalis.

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

G. Cicero, V. Franco, V. Serretta, 2015, Urology annals.

[Conservative management and survival of patients affected by T1G3 bladder tumours. When shall we indicate it and when the cystectomy?].

V. Zaccone, F. Aragona, V. Serretta, 2009, Urologia.

The Prognostic Value of P53 in Predicting of Bladder Carcinoma

V. Morello, V. Serretta, C. Pavone, 2005 .